A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial

HIV Clinical Trials

Volumn 11, Issue 5, 2010, Pages 260-269

  Young, Benjamin ^a,b   Vanig, Thanes ^c   DeJesus, Edwin ^d   Hawkins, Trevor ^e   St Clair, Marty ^f   Yau, Linda ^f   Ha, Belinda ^f  

^a Rocky Mountain CARES/DIDC   (United States)

^b Health Connections International   (Netherlands)

^c Spectrum Medical Group   (United States)

^d ORLANDO IMMUNOLOGY CENTER   (United States)

^e Southwest CARE Center   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

abacavir; HIV; integrase; lamivudine; raltegravir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; CHOLESTEROL; HEPATITIS B SURFACE ANTIGEN; HLA B ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; RALTEGRAVIR;

ADULT; AFFECT LABILITY; ANXIETY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; INSOMNIA; MALE; NAUSEA; NIGHT SWEAT; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VOMITING;

ADULT; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-6; LAMIVUDINE; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; TRIGLYCERIDES;

EID: 79251630271     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1105-260     Document Type: Article

References (21)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009;1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 15, 2010.
2. Smith C and D:A:D Study Group. Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: the data collection on adverse events of anti-HIV drug study. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada. Abstract 145.
3. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133.
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
5. Smith K Y, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
6. Elion R, de Jesus E, Sension M, et al. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008;9:152-163.
7. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90:22i-29i.
8. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387.
9. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107; 499-511.
10. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;15:1788-1795.
11. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med. 2008;16:62-68.
12. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS. 2004;18:1691-1696.
13. Quan Y, Brenner BG, Oliveira M, et al. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother. 2003;47:747-754.
14. Katlama C, Clotet B, Plettenberg A, et al. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med. 2001;2:27-34.
15. Miller V, Stürmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS. 1998;12:705-712.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-3421.
17. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22:1890-1892.
18. Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDS. 2009;23:689-690.
19. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22:1382-1384.
20. Masiá M, Enríquez R, Sirvent A, et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect. 2010;61:189-190.
21. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207:524-529.